M. Peeters

发表

A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.

P. Rougier, J. Infante, J. Stephenson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic chemotherapy in patients with peritoneal carcinomatosis from non colorectal origin.

H. Denys, S. van Lierde, M. Peeters, 2007, Cancer treatment and research.

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Hartmann, A. Zaniboni, T. Price, 2010 .

Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels

P. Pattyn, T. Boterberg, P. Demetter, 2007, British Journal of Cancer.

Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT).

P. Flamen, M. Paesmans, J. Van Laethem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

G. Giaccone, R. Stupp, Y. Humblet, 2005 .

Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study

P. Gibbs, Tae Won Kim, T. Price, 2016 .

EGFR and K-RAS gene status evaluation in anal canal squamous cell carcinoma

F. Speleman, P. Pauwels, N. Roy, 2008 .

Inflammatory bowel disease in spouses and their offspring.

S. Vermeire, É. Lerebours, J. Colombel, 2001, Gastroenterology.

Physician compliance and relapse rates of acute lymphoblastic leukemia in children

G. Koren, A. Zipursky, M. Peeters, 1988, Clinical pharmacology and therapeutics.

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases

C. Van de Wiele, R. Troisi, L. Libbrecht, 2012, British Journal of Cancer.

Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining.

A. Santoro, T. Ciuleanu, P. Mainwaring, 2010 .

Date of birth in familial Crohn's disease suggests environmental factors

J. Belaiche, A. Gossum, J. Hugot, 1998 .